Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of its Juvéderm VOLUX dermal filler product in China. Juvéderm VOLUX is a hyaluronic acid-based product specifically designed for contouring the lower jaw area. It is used for injection onto the facial periosteum to enhance the mandibular contour in patients with moderate mandibular retrognathia. Clinical studies have demonstrated that the product can maintain clear and sharp jawlines for an extended period of up to 18-24 months. The inclusion of lidocaine in Juvéderm VOLUX helps to reduce patient discomfort during treatment, thereby improving overall treatment comfort.- Flcube.com
Recent news:
-
Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies -
Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation -
DeepSeek's Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation -
Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development -
Roche's Itovebi Approved in China for PIK3CA-Mutated Breast Cancer
